IL263372B2 - Treatments for cholestatic liver diseases - Google Patents
Treatments for cholestatic liver diseasesInfo
- Publication number
- IL263372B2 IL263372B2 IL263372A IL26337218A IL263372B2 IL 263372 B2 IL263372 B2 IL 263372B2 IL 263372 A IL263372 A IL 263372A IL 26337218 A IL26337218 A IL 26337218A IL 263372 B2 IL263372 B2 IL 263372B2
- Authority
- IL
- Israel
- Prior art keywords
- liver
- compound
- cholestasis
- bile
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Farming Of Fish And Shellfish (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662343688P | 2016-05-31 | 2016-05-31 | |
| PCT/US2017/029620 WO2017209865A1 (en) | 2016-05-31 | 2017-04-26 | Treatment of intrahepatic cholestatic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL263372A IL263372A (en) | 2018-12-31 |
| IL263372B2 true IL263372B2 (en) | 2023-06-01 |
Family
ID=58699276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL263372A IL263372B2 (en) | 2016-05-31 | 2018-11-29 | Treatments for cholestatic liver diseases |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US10272058B2 (https=) |
| EP (1) | EP3463328B1 (https=) |
| JP (1) | JP7079735B2 (https=) |
| KR (1) | KR102408288B1 (https=) |
| CN (2) | CN109195594A (https=) |
| AU (1) | AU2017274293B2 (https=) |
| BR (1) | BR112018074147A2 (https=) |
| CA (1) | CA3024155C (https=) |
| CY (1) | CY1125465T1 (https=) |
| DK (1) | DK3463328T3 (https=) |
| ES (1) | ES2921230T3 (https=) |
| HR (1) | HRP20220903T1 (https=) |
| HU (1) | HUE059838T2 (https=) |
| IL (1) | IL263372B2 (https=) |
| LT (1) | LT3463328T (https=) |
| MX (1) | MX390417B (https=) |
| NZ (1) | NZ748721A (https=) |
| PL (1) | PL3463328T3 (https=) |
| PT (1) | PT3463328T (https=) |
| RS (1) | RS63345B1 (https=) |
| RU (1) | RU2765460C2 (https=) |
| SG (1) | SG11201810123SA (https=) |
| SI (1) | SI3463328T1 (https=) |
| SM (1) | SMT202200471T1 (https=) |
| UA (1) | UA122719C2 (https=) |
| WO (1) | WO2017209865A1 (https=) |
| ZA (1) | ZA201808360B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3119384T (pt) | 2014-03-20 | 2018-12-12 | Cymabay Therapeutics Inc | Tratamento de doenças colestáticas intra-hepáticas |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| WO2020102337A1 (en) * | 2018-11-16 | 2020-05-22 | Cymabay Therapeutics, Inc. | Combination treatment of nafld and nash |
| FI4225291T3 (fi) * | 2021-02-01 | 2024-06-03 | Cymabay Therapeutics Inc | Kolangiopatioiden hoito seladelpaarilla |
| WO2024180642A1 (ja) | 2023-02-28 | 2024-09-06 | 株式会社日立ハイテク | プラズマ処理装置およびプラズマ処理装置の試料台の製造方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015143178A1 (en) * | 2014-03-20 | 2015-09-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| AU5359496A (en) | 1995-03-06 | 1996-09-23 | Isis Pharmaceuticals, Inc. | Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| ATE267207T1 (de) | 1996-02-14 | 2004-06-15 | Isis Pharmaceuticals Inc | Kohlenhydratmodifizierte luckenhafte oligonukleotide |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US7981915B2 (en) | 2003-04-30 | 2011-07-19 | Beth Israel Deaconess Medical Center | Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene |
| EP1667964B1 (en) | 2003-09-19 | 2009-07-22 | Janssen Pharmaceutica N.V. | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| US7932268B2 (en) | 2004-03-05 | 2011-04-26 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| JP5694941B2 (ja) | 2008-10-17 | 2015-04-01 | シーマベイ セラピューティクス，インコーポレイティド | 小型高密度ｌｄｌ粒子を減少させる方法 |
| NZ624963A (en) * | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| MA34097B1 (fr) | 2010-03-30 | 2013-03-05 | Novartis Ag | Utilisations d'inhibiteurs de dgat1 |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20160279085A1 (en) | 2013-11-20 | 2016-09-29 | Cymabay Therapeutics, Inc. | Treatment of Severe Hyperlipidemia |
| HK1224186A1 (zh) | 2013-11-20 | 2017-08-18 | Cymabay Therapeutics, Inc. | 纯阖家族型高胆固醇血症的治疗 |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| BR112016023269A8 (pt) | 2014-04-11 | 2021-06-29 | Cymabay Therapeutics Inc | uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica |
| EA201790091A1 (ru) | 2014-06-26 | 2017-07-31 | Саймабэй Терапьютикс, Инк. | Лечение тяжелой гипертриглицеридемии |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| SMT202200171T1 (it) | 2017-09-26 | 2022-05-12 | Cymabay Therapeutics Inc | Trattamento del prurito colestatico con seladelpar |
| CA3118965A1 (en) | 2018-11-16 | 2020-05-22 | Cymabay Therapeutics, Inc. | Treatment of obesity and its complications |
| WO2020102337A1 (en) | 2018-11-16 | 2020-05-22 | Cymabay Therapeutics, Inc. | Combination treatment of nafld and nash |
-
2017
- 2017-04-25 US US15/496,875 patent/US10272058B2/en active Active
- 2017-04-26 SG SG11201810123SA patent/SG11201810123SA/en unknown
- 2017-04-26 PL PL17722943.2T patent/PL3463328T3/pl unknown
- 2017-04-26 HR HRP20220903TT patent/HRP20220903T1/hr unknown
- 2017-04-26 MX MX2018014915A patent/MX390417B/es unknown
- 2017-04-26 SM SM20220471T patent/SMT202200471T1/it unknown
- 2017-04-26 RS RS20220620A patent/RS63345B1/sr unknown
- 2017-04-26 AU AU2017274293A patent/AU2017274293B2/en active Active
- 2017-04-26 PT PT177229432T patent/PT3463328T/pt unknown
- 2017-04-26 DK DK17722943.2T patent/DK3463328T3/da active
- 2017-04-26 ES ES17722943T patent/ES2921230T3/es active Active
- 2017-04-26 CN CN201780033512.XA patent/CN109195594A/zh active Pending
- 2017-04-26 CA CA3024155A patent/CA3024155C/en active Active
- 2017-04-26 EP EP17722943.2A patent/EP3463328B1/en active Active
- 2017-04-26 NZ NZ748721A patent/NZ748721A/en unknown
- 2017-04-26 JP JP2018562567A patent/JP7079735B2/ja active Active
- 2017-04-26 HU HUE17722943A patent/HUE059838T2/hu unknown
- 2017-04-26 KR KR1020187037704A patent/KR102408288B1/ko active Active
- 2017-04-26 LT LTEPPCT/US2017/029620T patent/LT3463328T/lt unknown
- 2017-04-26 UA UAA201811776A patent/UA122719C2/uk unknown
- 2017-04-26 RU RU2018146504A patent/RU2765460C2/ru active
- 2017-04-26 CN CN202610013198.XA patent/CN121466055A/zh active Pending
- 2017-04-26 SI SI201731175T patent/SI3463328T1/sl unknown
- 2017-04-26 WO PCT/US2017/029620 patent/WO2017209865A1/en not_active Ceased
- 2017-04-26 BR BR112018074147-7A patent/BR112018074147A2/pt not_active Application Discontinuation
-
2018
- 2018-11-29 IL IL263372A patent/IL263372B2/en unknown
- 2018-12-11 ZA ZA2018/08360A patent/ZA201808360B/en unknown
-
2019
- 2019-03-28 US US16/367,660 patent/US10478411B2/en active Active
- 2019-10-09 US US16/597,313 patent/US10813895B2/en active Active
-
2020
- 2020-09-18 US US17/024,971 patent/US11000494B2/en active Active
-
2021
- 2021-04-03 US US17/221,784 patent/US11596614B2/en active Active
-
2022
- 2022-08-04 CY CY20221100534T patent/CY1125465T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015143178A1 (en) * | 2014-03-20 | 2015-09-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263372B2 (en) | Treatments for cholestatic liver diseases | |
| US11406611B2 (en) | Treatment of intrahepatic cholestatic diseases | |
| JP2019533706A (ja) | 肝疾患を処置する方法 | |
| JP2010501472A (ja) | 炎症性腸疾患および癌の治療におけるｏ−グリカン | |
| JP2024504555A (ja) | 急性膵炎を予防及び治療するための薬物の製造におけるノルハルマンの使用 | |
| US20200129460A1 (en) | Treatment of intrahepatic cholestatic diseases | |
| US11400137B2 (en) | Rectal insulin for treatment of inflammatory bowel diseases | |
| CN114652746A (zh) | 纳米钨或氧化钨在制备胃肠道炎症的药物中的应用 | |
| CN102631354B (zh) | 含维生素d3和二甲双胍的药物组合物 | |
| Hiser et al. | Pierson syndrome in an infant with congenital nephrotic syndrome and unique brain pathology | |
| Suarez-de-la-Rica et al. | Severe cefepime-induced status epilepticus treated with haemofiltration | |
| CN103599108B (zh) | 齐墩果酸在制备预防和治疗胆汁淤积症药物中的应用 | |
| US20060252735A1 (en) | Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone | |
| Plato et al. | S4135 Ischemic Colitis Following Tirzepatide Therapy: An Emerging Clinical Observation | |
| WO2025147565A1 (en) | Treatment of necrotizing enterocolitis and symptoms thereof | |
| Tursi et al. | Budesonide MMX (TM) Is Effective in Patients Having Persistent Symptoms and Raised Fecal Calprotectin Following Treatments for Diverticular Disease | |
| Han et al. | Intestinal Epithelial Cell-derived Osteopontin Protects Against Metabolic Dysfunction–associated Steatohepatitis by Modulating Bile Acid Composition and the Gut Microbiome | |
| Aliasi-sinai et al. | S4138 Hyperammonemia Following Roux-en-Y Gastric Bypass: A Life-Threatening Complication | |
| Diraviam et al. | S4137 Beyond Nausea: A Case of Colonic Bowel Obstruction Linked to GLP-1 Agonist Use | |
| Elena et al. | S4136 Histamine Intolerance: Diverse Gastrointestinal Manifestations and Diagnostic Challenges | |
| EP4061357A1 (en) | Use of sglt2 inhibitors to treat primary billiary cholangitis | |
| Simmelink et al. | 2052 Crohn's Disease and Rare Renal Extra-Intestinal Manifestations: Two Case Reports | |
| Doktorova | Intestinal nuclear receptor signaling in cystic fibrosis | |
| Siegmund et al. | Standards of medical treatment and nutrition in Crohn’s disease | |
| Armuzzi et al. | OC. 06.3 ADALIMUMAB IN ACTIVE ULCERATIVE COLITIS: A “REAL-LIFE” OBSERVATIONAL STUDY |